Weight ManagementJune 7, 2026·5 min read
By the CIRRUS Editorial Team — how we write and source this
GLP-1 drugs for teens: what the guidelines actually require before prescribing
Two GLP-1 drugs are FDA-approved for adolescents with obesity starting at age 12. Usage is rising fast, and the guidelines around when it's appropriate are more specific than a BMI cutoff.
Wegovy (weekly semaglutide) and Saxenda (daily liraglutide) are currently FDA-approved for adolescents age 12 and older with obesity, defined using age- and sex-specific growth chart percentiles rather than the fixed BMI thresholds used for adults. Usage has grown rapidly among adolescents and young adults treated for obesity in recent years, with GLP-1 drugs now the dominant treatment choice by a wide margin over bariatric surgery in this age group — a significant shift from just a few years ago when surgical options and lifestyle intervention alone were the primary tools available.
Clinical trial data in adolescents has generally shown meaningful weight loss — reported in the range of roughly 5% to 16% of body weight depending on the specific drug and study — combined with lifestyle intervention, broadly consistent with adult trial results, though the adolescent evidence base remains considerably smaller than the adult one given the more recent approval timeline and understandably more cautious pace of pediatric drug research generally.
Guidelines for prescribing in this age group emphasize that medication should be one component of a broader treatment approach that includes nutrition and behavioral support, not a standalone intervention, and that the decision involves the family and adolescent directly given the open questions that remain — including long-term safety data still being gathered as this treatment population matures, and unresolved questions about optimal treatment duration and how medication should be sequenced relative to bariatric surgery for adolescents with the most severe obesity.
For families considering GLP-1 treatment for an adolescent, working with a pediatric obesity specialist or pediatric endocrinologist — rather than a general prescriber less familiar with the specific adolescent trial data and guideline nuances — is worth prioritizing, given how actively this area of pediatric treatment guidance continues to evolve.
This article is general health information, not medical advice, and doesn’t replace evaluation by your own physician. Talk to a doctor about anything specific to your own diagnosis or treatment.